about
P184
Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and managementThe insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endotheliumIn silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesisSomatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts.Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event.Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-A.Prospective development and validation of a model to predict heart failure hospitalisationEffect of transglutaminase 2 (TG2) deficiency on atherosclerotic plaque stability in the apolipoprotein E deficient mouse.Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contractionEffects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans.A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study.Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regenerationIGF-binding protein-2 protects against the development of obesity and insulin resistancePrognosis in heart failure with preserved left ventricular systolic function: prospective cohort study.Inspiratory muscle load and capacity in chronic heart failure.Predicting sudden death in patients with mild to moderate chronic heart failure.Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosisNovel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice.Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure.Changing the way we think about endothelial cell insulin sensitivity, nitric oxide, and the pathophysiology of type 2 diabetes: the FoxO is loose.Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.Diurnal variation in vascular and metabolic function in diet-induced obesity: divergence of insulin resistance and loss of clock rhythm.Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction.Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study.Insulin resistance and endothelial cell dysfunction: studies in mammalian models.Insulin and endothelial function: physiological environment defines effect on atherosclerotic risk.The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease.Role of IGF-1 in glucose regulation and cardiovascular disease.IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis.Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.Insulin resistance, lipotoxicity and endothelial dysfunction.The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease.The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.Importance of insulin resistance to vascular repair and regeneration.Patients with long-term permanent pacemakers have a high prevalence of left ventricular dysfunction.Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure.Piezo1 channels sense whole body physical activity to reset cardiovascular homeostasis and enhance performance.Endothelial IGF-1 Receptor Signalling in Diabetes and Insulin Resistance.Insulin-Like Growth Factor Binding Protein 1 Could Improve Glucose Regulation and Insulin Sensitivity Through Its RGD Domain.
P50
Q28345278-9717C3FB-7CEC-4827-9FB1-54F5E013DBF6Q28508627-c4653b57-4147-b42b-1759-e52f6a8333a7Q28544931-2415D8E4-DDA5-4BC8-BC53-00A06457EE9DQ33232091-317F403D-6401-438E-A63D-BCC4371F9452Q33378481-BDA4F112-800D-4775-8F24-37777D00E40BQ33442546-707951D7-F3FA-4820-B581-29C0CA690202Q33659469-AD060CFC-85D7-4E1C-81BB-AB16CAC7DA56Q33870355-342D680A-169E-455A-B304-2C32FD5E4EF8Q33881782-FE04A388-4A3F-4084-8369-2E61B8E2D69DQ33968345-8C2C11E6-0347-4149-AAAE-6B025605CE50Q34472013-7988B53F-4FAB-4E72-9237-72BACD0B81BAQ34556389-FE2746DC-E88D-45F9-904D-98868B786C9BQ34718887-820BE2E1-4ABC-498F-A387-7AD5B18CCB17Q34966710-879B0939-84D9-4994-B403-30803B61E8E6Q35151695-33F7FE4B-07F7-4EFF-8DE6-B97387419374Q35536708-731A480F-DB94-4EDA-B1DD-E03214187383Q35582942-5AF0B1FB-AE24-4423-8A7E-BFB672999DF0Q35857746-EA12FA26-BC70-4D3D-AFB9-659CF707E92BQ36182530-9E337293-C2D1-46FF-A437-0E51DD6833F0Q36577192-F8246C42-17F6-411C-97FD-F3B274939DFBQ36796121-B4FF723C-D0D3-447A-8278-BEBB1C1ECFEFQ36859699-1E2B483C-8F18-45B1-A7E6-11650C640E41Q36867458-4CFDC5B5-F351-42C2-B30E-C6024DE60FBDQ36867557-C4FEFFD1-EC9B-469B-A8BD-57CA94AA0B90Q36968934-3F1948CF-F4DF-4D94-8FEB-0C0E291D9768Q36969764-E89C525E-5FC7-4A53-8240-15EEF5333D4FQ37065605-7BFB79C6-B25E-4C8E-B49F-B27BC56E2A17Q37082951-2A9F416F-FCED-4756-95DF-6C779CDD36A1Q37269401-5D0B12A6-564B-4ABC-AA51-DAA6B7492C37Q37435220-7B5A876A-C15B-4994-A3E2-A96E7CE06193Q37462316-33E52FBA-E103-49F5-83BE-10A3C5E16EB5Q37612301-774ECB7E-96AF-4E05-95D4-43182B195593Q37807986-0ADF95EE-E621-4404-BFB5-DEB8F9814A71Q38075845-D183EEDF-55C6-46D1-8AFC-CB3D6A88A5A6Q38087157-2B74CE15-1AF9-4401-8FCD-58D54DCBB459Q38224672-12C83841-1D64-4E64-ACD0-E561AA5B96EDQ38373783-4A0DFC12-0031-40EF-86C5-39B95F29EAF9Q38609430-6D5664DB-55C7-4602-A6F9-DB036D6D11FCQ38681988-9DAE3A33-B98E-42F1-86FC-095A51A08DA7Q38720235-FB24706F-270A-42B4-A9F9-1A7AB29DC679
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Mark Kearney
@ast
Mark Kearney
@cy
Mark Kearney
@en
Mark Kearney
@en-gb
Mark Kearney
@es
Mark Kearney
@la
Mark Kearney
@nl
Mark Kearney
@sl
type
label
Mark Kearney
@ast
Mark Kearney
@cy
Mark Kearney
@en
Mark Kearney
@en-gb
Mark Kearney
@es
Mark Kearney
@la
Mark Kearney
@nl
Mark Kearney
@sl
altLabel
Mark T. Kearney
@cy
Mark T. Kearney
@en
Mark T. Kearney
@en-gb
Mark T. Kearney
@la
prefLabel
Mark Kearney
@ast
Mark Kearney
@cy
Mark Kearney
@en
Mark Kearney
@en-gb
Mark Kearney
@es
Mark Kearney
@la
Mark Kearney
@nl
Mark Kearney
@sl
P214
P244
P106
P1153
7102876612
P185
P2031
1995-01-01T00:00:00Z
P21
P213
0000 0000 4072 3589
P214
P244
n2007037432
P31
P734
P735
P7859
lccn-n2007037432